Incretin Therapies in the Management of Elderly Patients with Type ...

Incretin therapies in the management of elderly patients with type 2 ...

Aging is characterized by a progressive increase in the prevalence of type 2 diabetes mellitus (T2DM), which approaches 20% by age 70 years. Older patients ...

New approaches to treating type 2 diabetes mellitus in the elderly

There is strong evidence that use of incretin therapy, in particular, the DPP-4 inhibitors, could offer significant advantages in older persons. Clinical ...

Incretin Therapies in the Management of Elderly Patients with Type ...

Abstract: Aging is characterized by a progressive increase in the prevalence of type 2 diabetes mellitus (T2DM), which approaches 20% by age 70 years. Older ...

Incretin therapies in the management of elderly patients with type 2 ...

"Incretin therapies," comprising the injectable GLP-1 analogs and oral dipeptidyl peptidase-4 (DPP-4) inhibitors, are promising new therapies for use in older ...

Focus on Incretin-Based Therapies for Elderly Patients with Type 2 ...

∙ Setter, S.M.. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009; 7:324-342. Abstract.

Incretin-related therapies therefore have a clear clinical utility in patients such as the elderly, who are at high risk of, or at extra risk ...

Incretin-Based Therapies in Complex Patients: Practical Implications ...

Older patients with type 2 diabetes—like patients with renal insufficiency an important and populous subgroup—also have issues with therapy selection and dosing ...

Incretin-Based Therapies in Complex Patients: Practical Implications ...

For both older patients and patients with chronic renal insufficiency, the most important drug-related adverse effect to avoid is hypoglycemia. Accordingly, ...

1007-P: Incretin Therapy with DPP-4-I and GLP1-RA for the Hospital ...

Management of hospitalized older adults (> 65 years) with T2D is challenging and associated with increased risk of hypoglycemia.

Incretin-Based Therapy Compared with Non-Insulin Alternatives in

Incretin agents lower glucose without weight gain and rarely cause hypoglycemia, but are expensive and lower glucose less than alternatives. A ...

Incretin Therapies for Patients with Type 2 Diabetes and Chronic ...

like peptide-1 (GLP-1) receptor agonists represent an important therapeutic class for the management of type 2 diabetes (T2D), demonstrating benefits beyond ...

Cognitive protection of incretin‐based therapies in patients with type ...

Current evidence shows that incretin-based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive ...

Incretin Therapies in the Management of Patients with Type 2 ...

In the overall population, they improve glycemic control in a glucose-dependent manner and are not likely to cause hypoglycemia, representing a ...

Incretin-Based Therapies in Complex Patients: Practical Implications ...

Elderly patients and patients with renal impairment present unique challenges in the management of diabetes mellitus. Impaired renal function is a common ...

Use of Incretin Therapy in the Treatment of Type 2 Diabetes Mellitus

GLP-1 RA and DPP-4 inhibitors are well-tolerated options that improve glycemic control with a low incidence of hypoglycemia and weight gain. •. This article ...

Incretin-based therapy: a powerful and promising weapon in the ...

The convenience and flexibility of antidiabetic regimens is known to positively impact treatment compliance.4 For example, elderly patients, ...

Incorporating Incretin-Based Therapies into Clinical Practice for ...

Data indicate and clinical experience confirms that incretins are well tolerated in appropriate patients and provide sustained glycemic control ...

Incretin Therapies in the Management of Elderly Patients with Type ...

Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus. Isabelle Bourdel-Marchasson. ,. Anja SCHWEIZER. ,. Sylvie Dejager.

Incretin based treatments and mortality in patients with type 2 diabetes

Conclusions Current evidence does not support the suggestion that incretin based treatment increases all cause mortality in patients with type 2 ...

Management of Type 2 Diabetes Mellitus in Older Adults

Vildagliptin is effective and well-tolerated in type 2 diabetic patients aged 75 years or older (mean age, 77 years) [40]. Sitagliptin also provides similar ...